Popular terms

Proliferation topics
Proliferation
Cell Proliferation
Differentiation
Cancer Cell
Antibodies
Progesterone
Specificity
Cancer Cells
Antimicrobial
Lymphocyte
Cell Differentiation
Homogeneous
Amino Acids
Wound Healing
Epithelial

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Proliferation patents



      

This page is updated frequently with new Proliferation-related patent applications.




Date/App# patent app List of recent Proliferation-related patents
04/07/16
20160096868 
 Mussel-inspired bioactive surface coating composition generating silica nanoparticles patent thumbnailMussel-inspired bioactive surface coating composition generating silica nanoparticles
The present invention relates to a fusion protein comprising a mussel adhesive protein and a silica-binding peptide linked to the mussel adhesive protein, a silica nanoparticle a silica connected to the fusion protein, a fusion protein-silica nanoparticle complex comprising the silica nanoparticle having bioactivity and adhesiveness for cell proliferation and accelerating the differentiation, a surface coating composition including the complex, its use, and a method of coating a surface using the surface coating composition.. .
Postech Academy-industry Foundation


04/07/16
20160096837 
 Substituted 1,2,3,4-tetrahydropyrido[3,4-e] pyrrolo[1,2-a]pyrimidines as kinase inhibitors patent thumbnailSubstituted 1,2,3,4-tetrahydropyrido[3,4-e] pyrrolo[1,2-a]pyrimidines as kinase inhibitors
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. .
Allergan, Inc.


04/07/16
20160096832 
 Kinase inhibitors patent thumbnailKinase inhibitors
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. .
Allergan, Inc.


04/07/16
20160095815 
 Substance for restoring normal co-expression and interaction between the lox and nrage proteins patent thumbnailSubstance for restoring normal co-expression and interaction between the lox and nrage proteins
The invention relates to the use of a substance for restoring normal co-expression and interaction between the lox and nrage proteins. The invention relates in particular to the use of an effective amount of at least one substance that modulates the expression and/or activity of the lox of seq id no: 1 and/or that modulates the expression and/or activity of the nrage of seq id no: 2 for modulating the interaction between the lox and nrage proteins to regulate the balance between the cellular proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between lox and nrage is absent or altered.
Université Claude Bernard Lyon 1


03/31/16
20160090420 
 Antagonist of the btla/hvem interaction for use in therapy patent thumbnailAntagonist of the btla/hvem interaction for use in therapy
Antagonist of the btla/hvem interaction for use in therapy the present invention relates to an antagonist of the btla/hvem interaction for use in therapy, wherein said antagonist increases the proliferation of vγ9vδ2 t cells.. .
Centre National De La Recherche Scintifique- Cnrs


03/31/16
20160090380 
 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof patent thumbnail2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc


03/31/16
20160089395 
 Compositions and methods for altering human cutaneous microbiome to increase growth of staphylococcus epidermidis and reduce staphylococcus aureus proliferation patent thumbnailCompositions and methods for altering human cutaneous microbiome to increase growth of staphylococcus epidermidis and reduce staphylococcus aureus proliferation
An antibacterial composition comprising arginine bicarbonate, zinc carbonate, preferably arginine bicarbonate and zinc carbonate (abzc), in combination, plus one or more physiologically acceptable excipients, administered for the modification of cutaneous microfloras, generally to inhibit the growth of pathogenic staphylococcus aureus bacteria by promoting the growth of non-pathogenic staphylococcus epidermidis bacteria.. .
The Research Foundation For The State University Of New York


03/31/16
20160089319 
 Actives for stimulating differentiation of keratinocytes to lighten hyperpigmented skin patent thumbnailActives for stimulating differentiation of keratinocytes to lighten hyperpigmented skin
A method is provided for identifying a material having an efficacy for reducing color contrast between a hyperpigmented skin lesion and skin surrounding the hyperpigmented skin lesion without directly affecting melanocytes or melanogenesis. The method includes the steps of applying a composition containing a material to be tested to the hyperpigmented skin lesion; and after an interval of time, observing whether the composition has effected at least one of inhibiting proliferation of keratinocytes, stimulating differentiation of keratinocytes, and improving compressive deformation of dermal papillae, in a basal layer of epidermis in the hyperpigmented lesion of skin..
Elc Management Llc


03/24/16
20160083776 
 Methods for measuring polymerase activity useful for sensitive, quantitative measurements of any polymerase extension activity and for determining the presence of viable cells patent thumbnailMethods for measuring polymerase activity useful for sensitive, quantitative measurements of any polymerase extension activity and for determining the presence of viable cells
A novel, highly sensitive, quantitative and rapid dpe-pcr assay is disclosed that can be used to enumerate prokaryotic cells when presenting a purified or selected cell type and that has the capability to reproducibly measure dna polymerase extension activity from less than 10 cfu of bacteria via coupling to bead lysis. Also disclosed is the potential for the dpe-pcr assay of the invention to universally detect microbes by testing a panel of microorganisms comprised of gram-negative bacteria, gram-positive bacteria and candida species.
Zeus Scientific, Inc.


03/24/16
20160083442 
 Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use patent thumbnailInhibitors of the t cell-specific alternative p38 activation pathway and methods of use
In t lymphocytes, p38 mitogen activated protein kinase (mapk) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and dna damage-inducible alpha (gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in t cells.
The U.s.a, As Represented By The Secretary Department Of Health And Human Services


03/24/16
20160083441 

Development of protein-based biotherapeutics that penetrate cell-membrane and induce anti-cancer effect - cell-permeable trefoil factor 1 (cp-tff1) in gastrointestinal track (git) cancer, polynucleotides encoding the same, and anti-cancer compositions comprising the same


The present study investigated the use of macromolecule intracellular transduction technology (mitt) to deliver biologically active tff1 protein into gastric cancer cells both in vitro and in vivo. Proteins engineered to enter cancer cells are supposed to suppress cell proliferation and survival, consistent with its role as a tumor suppressor.
Cellivery Therapeutics, Inc.


03/24/16
20160083421 

Compunds for enzyme inhibition


Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of n-terminal nucleophile (ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the n-terminus.
Onyx Therapeutics, Inc.


03/24/16
20160082067 

Method for treatment of prostatic hyperplasia and/or ameliorating urinary disturbance with banana flower extract


The present invention provides a method for treatment of prostatic hyperplasia with banana flower extract. Such banana flower extract can suppress the proliferation of prostate cells and their ability to synthesize dihydrotestosterone.
Tci Co., Ltd.


03/17/16
20160075997 

Kit of medium of inducing and amplifying hematopoietic stem cells


A kit of medium of inducing and amplifying hematopoietic stem cells, the kit includes medium of inducing and amplifying hematopoietic stem cell, and the medium of inducing and amplifying hematopoietic stem cell includes cell proliferation factors and cell differentiation inhibitors needed in proliferation of hematopoietic stem cells, and the formula of the medium of inducing and amplifying hematopoietic stem cell is: 80-100% (v/v) dmem/f12 basic medium, 0-1 μg/ml sonic hedgehog, 0-1 μg/ml delta1, 0-1 μg/ml flt3l, 0-1 μg/ml igfbp, 0-1 μg/ml scf, 0-1 μg/ml, angiopoietin, 0-1 μg/ml tpo, 0-1 μg/ml mbp, 0-1 μg/ml lif, 0-1 μg/ml tgf-β, 0-100 mm mtepa, and 1-5 mm nac.. .
Beijing Ginkgo Bioscience Co., Ltd.


03/17/16
20160075755 

Immunosuppressive tgf-ß signal converter


Embodiments of the disclosure concern cell therapy methods and compositions utilizing cells expressing at least a chimeric tgfβ receptor including the exodomain of a tgfβii receptor and an endodomain that is not from tgfβ receptor, thereby converting the negative signal of tgfβ for t cell proliferation into a t cell activation signal. In at least certain aspects, cells harboring the chimeric tgfβ receptor also harbor one or more chimeric antigen receptors..
Baylor College Of Medicine


03/17/16
20160075730 

New morpholinyl anthracycline derivatives


The present invention relates to new morpholinyl anthracycline derivatives which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them..
Nerviano Medical Sciences S.r.l.


03/17/16
20160075708 

Anti-angiogenesis compound, intermediate and use thereof


Disclosed are an anti-abnormal proliferation of angiogenesis compound represented by formula i, use and intermediate thereof. The compound has good effect against abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting vegfr2.
Zhongshan Ophthalmic Center, Sun Yat-sen University


03/17/16
20160075701 

2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof


Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc


03/17/16
20160075662 

Indazolyl- and indolyl-benzamide derivatives


Useful in the treatment and/or prevention of diseases and/or conditions related to cell proliferation, such as cancer, infection, inflammation and inflammation-associated disorders, and conditions associated with angiogenesis.. .

03/17/16
20160074393 

Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors


The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the hedgehog pathway (hhp); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.. .
Hedgepath Pharmaceuticals, Inc.


03/17/16
20160074392 

Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors


The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the hedgehog pathway (hhp); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.. .
Hedgepath Pharmaceuticals, Inc.


03/17/16
20160074391 

Means and methods for treating cancer


And methods of treating or preventing cell proliferation disorders comprising administering to a subject a therapeutically active amount or a preventive amount of such a compound.. .

03/17/16
20160074373 

Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs


Compositions and methods concern organic molecules that bind to human atox1 and ccs at the copper trafficking interface of these proteins. This binding suppresses copper trafficking, which leads to inhibition of cancer cell proliferation and tumor growth.
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences


03/10/16
20160070540 

Architecting and defining extensible methods and processes to build hybrid solutions


A method and system defines a mechanism to architect and define extensible methods and processes to build hybrid solutions. Solution templates provide a mechanism to architect and define the software development method in an extensible way and it enables the method architecture to be flexible to assemble method content and process elements only for those solution types that are necessary for a given solution.
International Business Machines Corporation


03/10/16
20160068863 

Methods for heart regeneration


Methods for heart regeneration are provided. The invention provided herein includes methods of modulating proliferation of cardiomyocytes using small molecules and micro rnas.
Salk Institute For Biological Studies


03/10/16
20160068846 

Modulation of androgen receptor expression


Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (ar) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.. .
Isis Pharmaceuticals Inc.


03/10/16
20160068841 

Cancer treatment methods using remote conditioning


Cancer treatment methods comprising a step of applying remote conditioning to the cancer subject, for example remote ischemic conditioning via several episodes of short-term limb occlusion. Upregulation and release of remote conditioning substances such as microrna 144/451 cluster endogenously caused by remote conditioning may be beneficial in reducing the growth and proliferation of malignant cells.
Lifecuff Technologies Inc.


03/10/16
20160068612 

Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b


Antibodies that specifically bind to cd38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2b proteins are provided. Anti-cd38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both cd38 and the receptor for ifn-alpha2b, as well as to induce apoptosis in such cells.
Teva Pharmaceuticals Australia Pty Ltd


03/10/16
20160068599 

Method for treating neuroendocrine cancer


Methods for decreasing proliferation and preventing or treating a neuroendocrine cancer using an n-methyl d-aspartate-associated (nmda) glutamate receptor antagonists or binding agent, such as an antibody, antibody fragment or peptide aptamer specific for a nmda glutamate receptor, are disclosed.. .
Trustees Of Dartmouth College


03/10/16
20160068584 

Cytokine derived treatment with reduced vascular leak syndrome


The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an il-15 derivative conjugate so as to induce a proliferation of natural killer cells (nk cells) which is the same or higher than the one obtained with high dose of interleukin-2 (hdil-2); eventually associated with a pharmaceutically acceptable carrier.. .
Institut Gustave Roussy (igr)


03/10/16
20160068551 

3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof


Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc


03/10/16
20160068550 

3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof


Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc


03/10/16
20160068549 

3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof


Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc


03/10/16
20160068548 

3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof


Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc


03/10/16
20160068547 

3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof


Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc


03/10/16
20160068529 

3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof


Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the wnt pathway and/or of one or more of wnt signaling components.
Samumed, Llc


03/10/16
20160068525 

Fused heterocyclic compounds as selective bmp inhibitors


The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation..
Vanderbilt University


03/10/16
20160068496 

Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways


The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds.
Asana Biosciences, Llc


03/10/16
20160067260 

Compositions and methods for treating proliferation disorders


The present invention relates to methods of treating cell proliferative disorders, such as cancer or proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3h-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3h-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or n-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3h-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-n-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or proteus syndrome, by utilizing the above compounds in combination with ((r)-6-(2-fluorophenyl)-n-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine)..
Arqule, Inc.


03/03/16
20160060350 

Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations


The present invention relates to a monoclonal antibody directed against the cd20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence seq id no. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence seq id no.
Laboratoire Francais Du Fractionnement Et Des Biotechnologies


03/03/16
20160060323 

Zcytor17 heterodimeric cytokine receptor


Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto..
Zymogenetics, Inc.


03/03/16
20160060314 

Development of a protein-based biotherapeutic agent that penetrates cell-membrane and induces anti-tumor effect in solid tumors - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-tumor compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060312 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-pancreatic cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-pancreatic cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060311 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-lung cancer effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-lung cancer compositions comprising the same


In principle, protein-based biotherapeutics offers a way to control biochemical processes in living cells under non-steady state conditions and with fewer off-target effects than conventional small molecule therapeutics. However, systemic protein delivery in vivo has been proven difficult due to poor tissue penetration and rapid clearance.
Cellivery Therapeutics, Inc.


03/03/16
20160060310 

Development of protein-based biotherapeutics that penetrates cell-membrane and induces anti-hepatocellular carcinoma effect - improved cell-permeable suppressor of cytokine signaling (icp-socs3) proteins, polynucleotides encoding the same, and anti-hepatocellular carcinoma compositions comprising the same


Protein transduction exploits the ability of some cell-penetrating peptide (cpp) sequences to enhance the uptake of proteins and other macromolecules by mammalian cells. Previously developed hydrophobic cpps, named membrane translocating sequence (mts), membrane translocating motif (mtm) and macromolecule transduction domain (mtd), are able to deliver biologically active proteins into a variety of cells and tissues.
Cellivery Therapeutics, Inc.


03/03/16
20160060299 

Macrocyclic therapeutic agents and methods of treatment


The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Inc.


03/03/16
20160060221 

Substituted biaryl compound


Wherein, r1, w, r2, and z are as defined in the claims and the description, or a pharmacologically acceptable salt thereof. The compound according to the present invention has an excellent inhibition effect of pulmonary fibroblast proliferation, and is therefore useful as a therapeutic agent and/or a prophylactic agent for interstitial pneumonia and pulmonary fibrosis..

03/03/16
20160058923 

Compositions and methods for reducing neointima formation


Compositions, devices, grafts and methods for reducing or preventing anti-neointima following cardiovascular injuries and interventions are disclosed. The compositions, devices, and grafts typically include an effective amount of a ctp synthase 1 inhibitor to reduce proliferation of vascular smooth muscle cells, without substantial reducing the proliferation of endothelial cells.
University Of George Research Foundation, Inc.


03/03/16
20160058812 

Compositions for the treatment of peripheral ulcers of various origins


The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use..
Indena S.p.a.


03/03/16
20160058810 

Composition containing angelica extract for promoting proliferation of stem cells derived from bone marrow


The present invention relates to a composition for promoting proliferation of bone marrow derived stem cells using an angelicae gigantis radix extract, and more particularly, to a composition which administers a granulocyte colony-stimulating factor into an object, and administers the angelicae gigantis radix extract to the object to promote the proliferation of the bone marrow derived stem cells. The composition of the present invention solves side effects such as splenomegaly which were caused by a method of administering only the g-csf for proliferation and differentiation of the stem cells, thereby significantly mitigating the side effects through co-administration of the angelicae gigantis radix extract, and further promoting the proliferation and the differentiation of the stem cells..
Comprehensive And Integrative Medicine Institute


03/03/16
20160058807 

Composition containing bacterium belonging to genus lactobacillus


A composition containing a lactobacillus pentosus tua4337l strain (accession number: nite bp-1479), characterized in that the strain has proliferation ability in the small intestines and/or the large intestine, and preferably the small intestines, after having survived in the intestinal tract. Since the composition of the present invention contains lactic acid bacteria having proliferation ability in the intestinal tract, when ingested in the body, the lactic acid bacteria survive to the intestinal tract and proliferate, whereby the fat absorption can be blocked, and the weight gains can be blocked, so that the composition can be suitably used for the purposes of dieting effects..
Suntory Holdings Limited


03/03/16
20160058783 

Nucleoside and nucleotide derivatives


Which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by hiv, hcv or hbv. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents.

02/25/16
20160054303 

Compositions and assays for determining cell viability


Provided are compositions and methods useful in evaluation of cell health and metabolism, cell viability, proliferation, and the effects of compounds on these qualities. The assays provided are rapid, robust, nontoxic and suitable for use with high throughput devices..
Life Technologies Corporation


02/25/16
20160053391 

Methods of fabricating metallic fuel from surplus plutonium


A method of fabricating metallic fuel from surplus plutonium may include combining plutonium oxide powder and uranium oxide powder to obtain a mixed powder with reduced proliferation potential. The mixed powder may be electroreduced in a bath of molten salt so as to convert the mixed powder to a first alloy.
Ge-hitachi Nuclear Energy Americas Llc


02/25/16
20160053268 

Antiproliferative agent


The invention provides an antibody specific to the angptl4 protein capable of neutralizing proliferation and methods of making and using the same. The antibody of the invention is further directed to the c terminal region of the protein and may be capable of neutralizing cell proliferation and treating cancer.
Nanyang Technological University


02/25/16
20160053217 

Automatic stimulator for cell cultures based on vibrations


The present invention relates to an automatic stimulator based on vibrations for cell cultures, fulfilling the function of activating the proliferation of osteoprogenitor cells and of activating the expression of the genes involved in the process of cell differentiation toward the osteogenic line. This effect is produced in the cells by the application of mechanical vibrational load.
Universidad Militar Nueva Granada


02/25/16
20160053006 

Compositions and methods relating to inhibiting cancer cell growth and/or proliferation


The present invention determined that egfl6 functions as a tumor vascular regulator of ovarian cancer stem cells (csc). In addition, the present invention determined that a novel egfl6 blocking antibody was able to restrict cancer cell growth and delay disease recurrence.
The Regents Of The University Of Michigan


02/25/16
20160052979 

Family of synthetic polynucleotide-binding peptides and uses thereof


The present invention provides novel synthetic peptides (including the tzip peptide) as oncogenic and genetic modulators, including genetics of viruses, as well as methods of making and using the same. These peptides are useful for inhibiting the proliferation of cancer cells characterized as having amplified c-myc genes.
Eastern Virginia Medical School


02/25/16
20160052952 

Substituted gemcitabine bicyclic amide analogs and treatment methods using same


In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating viral disorders and disorders of uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..

02/25/16
20160052880 

Novel cc-1065 analogs and their conjugates


This invention relates to novel analogs of the dna-alkylating agent cc-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates.
Syntarga Bv


02/25/16
20160051674 

Methods and pharmaceutical compositions (ctps 1 inhibitors, e.g. norleucine) for inhibiting t cell proliferation in a subject in need thereof


The present invention relates to methods and pharmaceutical compositions for inhibiting lymphocyte proliferationin a subject in need thereof. In particular, the invention relates to a ctp synthase 1 (ctps1) inhibitor for use in a method for inhibiting lymphocyte proliferationin a subject in need thereof.
The Universty Of Manchester


02/25/16
20160051669 

Compositions and methods for selectively modulating tregs


It has been discovered that pik3δ (pik3delta) selectively modulates the activation and proliferation of natural tregs. Methods of modulating immune responses by modulating pik3δ bioavailability or biological activity are provided..
Georgia Regents University Research Institute, Inc.


02/25/16
20160051558 

Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells


The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1h-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator t cells from undifferentiated t cells and/or promoting proliferation of regulator t cells.. .
Lg Life Sciences Ltd.


02/25/16
20160051505 

Compounds and methods for delivery of prostacyclin analogs


This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.. .
United Therapeutics Corporation


02/25/16
20160051501 

Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders


The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease..
Genfit


02/25/16
20160051423 

Absorbent article


Absorbent article suppressing occurrence of malodor after use while preventing a rash on a wearer's skin. The absorbent article includes an absorbent body, and a fumaric acid-supported sheet disposed on a skin surface side of the absorbent body.
Livedo Corporation


02/18/16
20160046941 

Targeting micrornas for the treatment of liver cancer


Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a mirna.
Rosetta Genomics Ltd.


02/18/16
20160046761 

Biodegradable side chain liquid crystal elastomers: smart responsive scaffolds (srs) for tissue regeneration


Controlled biodegradable smart responsive scaffold (srs) materials enhance attachment and viability of cells, i.e. Actively guiding their expansion, proliferation and in some cases differentiation, while increasing their biomechanical functionality is an important key issue for tissue regeneration.
Kent State University


02/18/16
20160046706 

Antibody against human nrg1 protein


An object is to provide an antibody capable of specifically recognizing a human nrg1 protein isoform, and suppressing signal transduction in which the isoform is involved. An antibody capable of binding to a region at positions 221 to 234 of a human nrg1-α protein or an antibody capable of binding to a region at positions 213 to 239 of a human nrg1-β1 protein was successfully obtained.
Medical & Biological Laboratories Co., Ltd.


02/18/16
20160046669 

Method for inhibiting proliferation of high lix1i-expressing tumor cell, and tumor cell proliferation-inhibiting peptide


A method is provided for inhibiting proliferation of a high lix1l-expressing tumor cell, in which the expression or function of a lix1l gene with respect to a tumor cell highly expressing the lix1l gene is inhibited.. .
National University Corporation Hamamatsu University School Of Medicine


02/18/16
20160046633 

Bmp inhibitors and methods of use thereof


The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with bmp signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
The U.s.a., As Represented By The Secretary, Department Of Health & Human Services


02/18/16
20160046611 

Novel chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders


The present invention relates to novel chromone alkaloid of formula 1 isolated from the plant dysoxylum binectariferum. The compound 5,7-dihydroxy-6-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4h-chromen-4-one, is found to be a potential inhibitor of cell growth and proliferation and also inhibits production of pro-inflammatory cytokines.
Council Of Scientific & Industrial Research


02/18/16
20160046578 

Inhibitors of prmt5 and methods of their use


In one aspect, the invention relates to prmt5 inhibitors, including optionally substituted n-alkyl-9h-carbazole analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation and benign hematologic diseases using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Ohio State Innovation Foundation


02/18/16
20160045506 

Use of inhibitors of binding between a par-1 receptor and its ligands for the treatment of glioma


The present invention relates to a method of treating glioma in a subject. The method comprises selecting a subject having a glioma, providing an inhibitor of binding between a par-1 receptor and a ligand of the par-1 receptor, and administering the inhibitor to the selected subject under conditions effective to treat the glioma and/or prevent spread of tumor cells.
University Of Rochester


02/11/16
20160040168 

Composition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient


The present invention relates to a composition for treatment or metastasis suppression of cancers which includes a p34 expression inhibitor or activity inhibitor as an active ingredient. According to the present invention, the p34 protein knock-down causes monoubiquitination of pten and accordingly nuclear localization of pten is induced, as a result, an akt pathway which is related to survival, proliferation, invasive properties and metastatic properties of tumors is inhibited, and thus there is an effect of significantly reducing clonogenic potential and tumor forming potential of various cancer cells which simultaneously express pten and nedd4-1.
University Of Ulsan Foundation For Industry Cooperation


02/11/16
20160039905 

B7-h4 fusion proteins and methods of use thereof


Fusion proteins containing b7-ii4 polypeptides are disclosed. The b7-h4 fusion proteins can include full-length b7-h4 polypeptides, or can contain a fragment of a full-length b7-h4 polypeptide, including some or all of the extracellular domain of the b7-h4 polypeptide.
Amplimmune, Inc.


02/11/16
20160039877 

Compositions and methods of using islet neogenesis peptides and analogs thereof


The invention provides peptides and analogs of ingap and hip peptides. The peptides and analogs can be used in methods for treating various diseases and conditions.
Shenzhen Hightide Biopharmaceutical, Ltd.


02/11/16
20160039814 

6-alkynyl-pyridine derivatives


Their use as smac mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. An exemplary compound is.

02/11/16
20160039802 

3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh


The invention is directed to a formula (i): or a pharmaceutically acceptable salt thereof, wherein r1, r2a, r2b and r3-r7 are described herein. The invention is also directed to compositions containing a compound of formula (i) and to the use of such compounds in the inhibition of mutant idh proteins having a neomorphic activity.
Novartis Ag


02/11/16
20160039761 

Heteroaryl compounds useful as inhibitors of e1 activating enzymes


This invention relates to compounds that inhibit e1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia..
Millennium Pharmaceuticals, Inc.


02/11/16
20160038760 

Conjunctival diseases


Provided herein are methods of treating conjunctival diseases, and methods of increasing the rigidity of a conjunctiva, decreasing the proliferation or number of conjunctival fibroblasts in a conjunctiva, and decreasing the number of immune cells present in a conjunctiva in a subject.. .
Massachusetts Eye And Ear Infirmary


02/11/16
20160038641 

Compounds and matrices for use in bone growth and repair


Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, transdifferentiation, and proliferation of animal cells into the osteoblast blast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of formula ii, iv, and vi independently or preferably in combination with a matrix to afford bone cells.
Human Biomolecular Research Institute


02/11/16
20160038476 

Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity


Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (ar), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, benign prostatic hyperplasia (bph), kennedy's disease, androgenetic alopecia, breast cancer, androgen-insensitive syndrome, and spinal and bulbar muscular atrophy..
University Of Maryland, Baltimore




Proliferation topics: Proliferation, Cell Proliferation, Differentiation, Cancer Cell, Antibodies, Progesterone, Specificity, Cancer Cells, Antimicrobial, Lymphocyte, Cell Differentiation, Homogeneous, Amino Acids, Wound Healing, Epithelial

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Proliferation for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Proliferation with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8366

5148

1 - 1 - 103